findmyKOL
Clinical trialNCT00004184CompletedPhase 1/PHASE2Interventional

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

SponsorUniversity of Alabama at BirminghamEnrollment50Melanoma (Skin)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Donald M. Miller, MD, PhD

    James Graham Brown Cancer Center at University of Louisville

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 1998
Primary completion
30 Jun 2001
Completion
30 Jun 2001
Last update posted
12 Apr 2013
Registered enrollment
50
Registry id
NCT00004184

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.